<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TECHNION-ISRAEL_Description skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TECHNION-ISRAEL/Description</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>navbar</TITLE></P><DIV class="container-fluid" style="margin-top:0px;"><DIV class="row"><DIV class="col-md-12"><NAV class="navbar navbar-inverse navbar-fixed-top " style=" z-index:800; position:fixed; margin:auto; width: 1180px ;"><DIV class="dropdown" style="padding-left: 100px;"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"><A href="https://2017.igem.org/Team:TECHNION-ISRAEL"> project </A></BUTTON><UL class="dropdown-menu" style=" margin: 0px;  left:78px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Description"> description </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Diseases"> Diseases &amp; Epitopes </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Design"><SPAN id="T">T</SPAN>ri-Display </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/delay_mechanism"><SPAN id="T">  T</SPAN>iming </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/kill_switch"><SPAN id="T">T</SPAN>erminate</A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Demonstrate"><SPAN id="T"> T</SPAN>olerance Assay </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"> wet lab 
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/cell_lines"> cell lines </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Results"> results </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/hpc7"> hpc-7 results </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Notebook"> notebook </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Experiments"> protocols </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/InterLab"> interlab </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Parts"> parts </A></BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Parts"> parts </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Basic_Part"> basic part </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Composite_Part"> composite part </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Part_Collection"> part collection </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Improve">	 improvement </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown" style="width: auto"> human practices 
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 18px; width: 170px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Silver"> HP silver </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Engagement"> Education &amp; Public Engagement </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Gold_Integrated"> integrated HP </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/ethics"> ethics </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"> judging
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px "><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Safety"> safety </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Collaborations"> collaboration </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Achievements"> achievements </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Model"> modelling </A></LI></UL></DIV><DIV class="dropdown" style="padding-right: 100px;"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown">team
							</BUTTON><UL class="dropdown-menu" style=" margin: 0px;  left: 2px;"><LI><A href=" https://2017.igem.org/Team:TECHNION-ISRAEL/Team"> members </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Attributions"> attributions </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/gallery"> gallery </A></LI></UL></DIV></NAV></DIV></DIV></DIV><P><TITLE>Description</TITLE></P><DIV class="container-fluid"><DIV class="row"><H1> Description </H1><DIV class="col-md-2"><DIV class="side"><UL class="sidelist hidden-sm" style="width:auto; padding-top:0px;"><LI><A class="cell" href="#pr"> The Problem </A></LI><LI><A class="cell" href="#im"> The Immune System </A></LI><LI><A class="cell" href="#imt"> Immune Tolerance </A></LI><LI><A class="cell" href="#de"> How autoimmune diseases and allergies develop </A></LI><LI><A class="cell" href="#cu">Current Treatment Options </A></LI><LI><A class="cell" href="#so">Our Solution </A></LI><LI><A class="cell" href="#vi">Vision </A></LI></UL></DIV></DIV><DIV class="col-md-8"><DIV class="row"><DIV class="col-md-12"><H3 id="pr"> The Problem </H3><P>
							Autoimmune disease and allergies are an increasingly common phenomenon in the Western world. An estimated 73 million people suffer from allergies and autoimmune disease in the United States alone. The prevalence of these diseases is on the rise. Scientists have developed many theories as to why this is happening: The hygiene 
							hypothesis
							<SUP id="cite ref-1 " class="reference"><A href="#ref1" original-title="">[1] </A></SUP>,
							increasing usage of antibiotics, certain common drugs and more. Regardless of the cause, with over $150 billion
							<SUP id="cite ref-2 " class="reference"><A href="#ref2" original-title="">[2] </A></SUP>
							 spent annually on health care for autoimmune diseases and allergies, this dire problem is quickly becoming untenable. 
							</P><H3 id="im"> The Immune System </H3><P>
							The immune system is a complex network of tissues, cells, and organs working in tandem to protect our bodies from disease. The <STRONG>Hematopoietic Stem Cell (HSC)</STRONG> is a multipotent, self-renewing, progenitor cell. All differentiated immune and blood cells arise from HSCs that exist in the bone marrow <STRONG>(figure 1)</STRONG>. 
							</P><P style="text-align:center;"><STRONG>Figure 1: </STRONG> Hematopoietic stem cell differentiation tree</P><H3 id="imt"> Immune Tolerance </H3><P>
								Immune tolerance is the lack of an immunological reaction to the presence of specific substances or tissues that have the capacity to induce an immune response. 
							
							Tolerance is maintained by <STRONG>two mechanisms</STRONG>: Central Tolerance and Peripheral Tolerance. Central Tolerance occurs in the primary lymphoid organs, namely the bone marrow cavities and the thymus, where immature B and T cells, respectively, develop. High affinity interaction between immature lymphocytes and antigens/epitopes present in the bone marrow, or thymus, leads to negative selection, and inactivation, of these reactive immune cells <STRONG>(figure 2)</STRONG>. 
							
							Peripheral Tolerance occurs in the immune periphery, after B and T cells exit the primary lymphoid organs, and is mediated by complex and varied interactions with antigen and other immune cells.
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><P style="text-align:center;"><STRONG>Figure 2: </STRONG> Central Tolerance within the bone marrow 
							
						
							Immature immune cells within the bone marrow undergoing selection. The red cell recognizes auto-antigen and as a result undergoes apoptosis. The orange immune cell does not recognize auto-antigen and is allowed to complete maturation
							
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><H3 id="de"> How autoimmune diseases and allergies develop </H3><P>
							The development of immune disease begins with loss of tolerance. In autoimmune disease there is a loss of tolerance to “self” <STRONG>(figure 3)</STRONG> whereas in allergic reactions there is loss of tolerance to specific external antigens which are harmless.  This loss of tolerance is referred to as sensitization. The exact mechanism through which tolerance is lost is still being investigated, and there appear to be multiple pathways involved in the onset of disease. 
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><P style="text-align:center;"><STRONG>Figure 3:  </STRONG>Disease causing immune cell escaping into the bloodstream
							
							
							
							An immature B-cell capable of recognizing auto-antigen somehow manages to mature and escape into the blood stream. This cell will potentially go on to cause the onset of autoimmune disease
							
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><H3 id="cu"> Current Treatment Options</H3><P>Many treatments for both autoimmune disease
							<SUP id="cite ref-3 " class="reference"><A href="#ref3" original-title="">[3] </A></SUP>
							and allergies,
							<SUP id="cite ref-4 " class="reference"><A href="#ref4" original-title="">[4] </A></SUP>
							such as immunosuppression and desensitization, have been attempted with varying degrees of success, but have largely been ineffective at curbing the prevalence of these conditions.  A single treatment modality for immune disorders has yet to be developed. Whilst allergic reactions and the many autoimmune diseases are quite distinct in their presentation and pathophysiology, they both stem from the improper, or unnecessary, activation of the immune system. This common etiology allows hope that one day a single treatment may be sufficient to cure or prevent both types of disease.
							</P><H3 id="so"> Our Solution</H3><P>We intend to design a preventative treatment for allergies and autoimmune disease. Through genetic engineering and subsequent transfusion of hematopoietic stem cells we hope to induce widespread and continuous immune tolerance towards specific antigens that are known causes of allergic and autoimmune 
							disease
							<SUP id="cite ref-5 " class="reference"><A href="#ref5" original-title="">[5] </A></SUP><SUP id="cite ref-6 " class="reference"><A href="#ref6" original-title="">[6] </A></SUP><SUP id="cite ref-7 " class="reference"><A href="#ref7" original-title="">[7] </A></SUP>. By utilizing the natural mechanism of Central Tolerance we intend to “educate” the immune system and make it tolerant to specifically targeted antigens. To do this, we are creating a plasmid based platform that will induce hematopoietic stem cells, and their differentiated lineages, to display target antigen on their membrane with the goal of inducing immune tolerance <STRONG>(figure 4)</STRONG>. While the specific antigens we are working on represent only a fraction of the existing diseases and allergies, they serve as proof of concept for a system that we hope will be modular, and effective enough to prevent many more autoimmune and allergic diseases.
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><P style="text-align:center;"><STRONG>Figure 4: </STRONG> Hematopoietic Stem Cell induced to present antigen on its surface
							
							
							after transfection with the ToloGen plasmid and genomic integration, the HSC expresses the desired epitopes on its membrane.
							
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><H3 id="so"> Prevention is the key</H3><P>
							Immunological memory poses a unique problem for HSC based gene therapy. Induction of tolerance will ideally prevent the maturation of harmful B and T cells, but the mechanisms involved do not directly affect existing plasma, and memory, immune cells. Only extreme and dangerous conditioning regiments
							<SUP id="cite ref-8 " class="reference"><A href="#ref8" original-title="">[8] </A></SUP>
							can eradicate these cells, and this would be unacceptable in a preventative treatment. Thus, patients already sensitized to self-antigen or external allergens will most likely not be cured, and will almost certainly reject any transplanted cells that present such antigens. For this reason we have chosen to focus on prevention, a fundamentally different and novel method for contending with autoimmune and allergic diseases. The ideal candidates for our proposed treatment are newborn babies who have limited immunological memory and development. HSCs can be <A target="_blank" href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Gold_Integrated">harvested from cord blood</A>, genetically engineered in a closed environment cell processing system, and transfused back into the child, all within 2-3 days <STRONG>(figure 5)</STRONG>. Finally, after 2-4 weeks, the genetically engineered HSCs will be induced to display the chosen antigens, engendering immune tolerance towards these epitopes. Of course, this proposed treatment raises many ethical questions. To see how we contend with these questions, please check out our <A target="_blank" href="https://2017.igem.org/Team:TECHNION-ISRAEL/ethics"> Ethics Handbook</A></P></DIV></DIV><DIV class="row"><DIV class="col-md-offset-2 col-md-8"><P style="text-align:center;"><STRONG>Figure 5: </STRONG> ToloGen Treatment Strategy
							<STRONG>1.</STRONG> Cord blood is harvested from new born babies.<STRONG> 2.</STRONG>CD34+ HSCs are isolated from the cord blood using magnetic beads and centrifugation. <STRONG>3.</STRONG> The HSCs are electroporated with the ToloGen plasmid.<STRONG> 4.</STRONG>The HSCs are transfused back into the baby.
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><H3 id="vi">Vision</H3><P>
							In the 20th century it is estimated that smallpox killed over 500,000,000 people. In 1980 the World Health Organization declared smallpox eradicated
							<SUP id="cite ref-9 " class="reference"><A href="#ref9" original-title="">[9] </A></SUP>. What was once unimaginable had been accomplished, the disease that had killed more people than all human wars put together, was destroyed. This amazing feat was not accomplished with a miracle cure, a previously unknown panacea, but with a vaccine. Sometimes an ounce of prevention, rather than a pound of cure, is the key. Autoimmune and allergic diseases pose an ever-growing medical and fiscal disaster. It is our hope that this research will help lead the way towards a new treatment paradigm for autoimmune and allergic disease. A paradigm founded on prevention. 
							</P><P>
							The children of tomorrow will never know the misery wrought upon mankind by the smallpox virus. We dream of a day when they will never know the misery of autoimmune diseases and allergies.
							</P><DIV class="references"><OL><LI id="ref1">Okada, H., et al. &quot;The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update.&quot;  <I>Clinical &amp; Experimental Immunology  </I>160.1 (2010): 1-9.</LI><LI id="ref2">  “Autoimmune Diseases Cost US More Than $100 Billion Annually.” MD Magazine, 28 Mar. 2011, www.mdmag.com/medical-news/autoimmune-diseases-cost-us-more-than-100-billion-annually http://www.aafa.org/page/allergy-facts.aspx. </LI><LI id="ref3">Rosenblum, Michael D. et al. “Treating Human Autoimmunity: Current Practice and Future Prospects.” <I> Science translational medicine </I>4.125 (2012): 125sr1. PMC. Web. 18 June 2017.</LI><LI id="ref4">Holgate, Stephen T., and Riccardo Polosa. &quot;Treatment strategies for allergy and asthma.&quot;<I> Nature Reviews Immunology </I>8.3 (2008): 218-230.</LI><LI id="ref5">Baranyi, U., et al. &quot;Persistent molecular microchimerism induces long‐term tolerance towards a clinically relevant respiratory allergen.&quot; <I>Clinical &amp; Experimental Allergy </I>42.8 (2012): 1282-1292.</LI><LI id="ref6">Pilat, Nina, and Thomas Wekerle. &quot;Transplantation tolerance through mixed chimerism.&quot;<I> Nature Reviews Nephrology</I> 6.10 (2010): 594-605.</LI><LI id="ref7">Alderuccio, Frank, et al. &quot;Hematopoietic stem cell gene therapy as a treatment for autoimmune diseases.&quot; <I>Molecular pharmaceutics </I>8.5 (2011): 1488-1494.</LI><LI id="ref8">Alexander, T., et al. &quot;Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases.&quot;  <I> Clin Exp Rheumatol </I>34.4 Suppl 98 (2016): S53</LI><LI id="ref9">Koplow, David A. Smallpox: the fight to eradicate a global scourge. Univ of California Press, 2004.</LI></OL></DIV></DIV></DIV></DIV></DIV></DIV><TITLE>My First Website</TITLE><DIV class="footer"><DIV class="container-fluid"><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><DIV class="row"><DIV class="col-md-4 nopadding"><DIV class="location"><P style="text-indent:inherit; margin-top: 30px; padding-bottom:15px;color:  #ffffff; 	font-family:  'Quicksand', sans-serif; 	font-size: 14px; 	line-height:25px; 	text-align: unset;">
											
							Department of Biotechnology &amp; Food Engineering
							
							
							Technion – Israel Institute of Technology
							
							
							Haifa 32000, Israel
							</P></DIV></DIV><DIV class="col-md-offset-3 col-md-3"><DIV class="contact" style="margin-top: 20px;"><UL><P style=" text-indent:inherit; margin-top: 5px; color:  #ffffff; font-family: 'Quicksand', sans-serif;	font-size: 14px;">
									igem.technion.2017@gmail.com
									</P></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>